SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-105919
Filing Date
2024-04-23
Accepted
2024-04-23 07:34:00
Documents
13
Period of Report
2024-04-22
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d823645d8k.htm   iXBRL 8-K 31400
  Complete submission text file 0001193125-24-105919.txt   159648

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fusn-20240422.xsd EX-101.SCH 2854
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fusn-20240422_lab.xml EX-101.LAB 18690
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fusn-20240422_pre.xml EX-101.PRE 11695
16 EXTRACTED XBRL INSTANCE DOCUMENT d823645d8k_htm.xml XML 3799
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 24862701
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)